BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31136750)

  • 1. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
    IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
    Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
    Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
    Front Immunol; 2021; 12():808964. PubMed ID: 35095898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
    Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
    Front Immunol; 2020; 11():550250. PubMed ID: 33193316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
    Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
    Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
    Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
    BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facts and Hopes in Colorectal Cancer Immunotherapy.
    Foote MB; Argilés G; Rousseau B; Segal NH
    Clin Cancer Res; 2023 Oct; 29(20):4032-4039. PubMed ID: 37326624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
    Guo L; Wang C; Qiu X; Pu X; Chang P
    Front Immunol; 2020; 11():1052. PubMed ID: 32547556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Role for MAIT Cells in Colorectal Cancer.
    Berzins SP; Wallace ME; Kannourakis G; Kelly J
    Front Immunol; 2020; 11():949. PubMed ID: 32508830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation.
    Giannini R; Zucchelli G; Giordano M; Ugolini C; Moretto R; Ambryszewska K; Leonardi M; Sensi E; Morano F; Pietrantonio F; Cremolini C; Falcone A; Fontanini G
    J Mol Diagn; 2020 May; 22(5):685-698. PubMed ID: 32173570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
    Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunotherapy Targeting Tumor-Associated Carbohydrate Antigens in Deficient Mismatch Repair Colorectal Cancer].
    Matsumoto T; Okayama H; Nakano H; Ito M; Nakajima S; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1275-1277. PubMed ID: 34657062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in
    Li Z; Lin J; Zhang L; Li J; Zhang Y; Zhao C; Wang H
    Future Oncol; 2020 Oct; 16(29):2295-2306. PubMed ID: 32639175
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges.
    Shahnazari M; Samadi P; Pourjafar M; Jalali A
    Future Oncol; 2021 Aug; 17(24):3253-3270. PubMed ID: 34156258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Association between Intestinal Bacteria and Tumor Infiltrating Immune Cells in the Tumor Microenvironment of Colorectal Cancer].
    Mimura K; Kikuchi T; Kono K
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1093-1095. PubMed ID: 34521782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategy to targeting the immune resistance and novel therapy in colorectal cancer.
    Gang W; Wang JJ; Guan R; Yan S; Shi F; Zhang JY; Li ZM; Gao J; Fu XL
    Cancer Med; 2018 May; 7(5):1578-1603. PubMed ID: 29658188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer.
    Giordano G; Pancione M
    WIREs Mech Dis; 2024; 16(1):e1631. PubMed ID: 37818781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.